Sintilimab in combination with stereotactic body radiotherapy and granulocyte-macrophage colony-stimulating factor in metastatic non-small cell lung cancer: The multicenter SWORD phase 2 trial

Abstract This single-arm, multicenter, phase 2 trial (NCT04106180) investigated the triple combination of sintilimab (anti-PD1 antibody), stereotactic body radiotherapy (SBRT) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in metastatic non-small cell lung cancer (NSCLC). With a media...

Cijeli opis

Bibliografski detalji

Glavni autori:	Jianjiao Ni, Xiaofei Wang, Lin Wu, Xinghao Ai, Qian Chu, Chengbo Han, Xiaorong Dong, Yue Zhou, Yechun Pang, Zhengfei Zhu
Format:	Artigo
Jezik:	Inglês
Izdano:	Nature Portfolio 2024-08-01
Serija:	Nature Communications
Online pristup:	https://doi.org/10.1038/s41467-024-51807-7
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!